search
Back to results

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Buprenorphine transdermal patch
Placebo
Sponsored by
Purdue Pharma LP
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring Chronic pain, opioid, transdermal, osteoarthritis

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: clinical diagnosis of chronic osteoarthritis of the hip or knee for 1 year or longer. an average pain due to osteoarthritis of moderate, moderately-severe, or severe for the 14 days prior to enrollment. Exclusion Criteria: ingest opioid analgesics on a daily basis. ingest >2500 milligrams (mg) acetaminophen on a daily basis. require <20 mg or >80 mg of morphine (or opioid equivalents) per day for control of their osteoarthritis pain. Other protocol-specific exclusion/inclusion criteria may apply.

Sites / Locations

  • Vista Medical Research
  • Arizona Research Center
  • Radiant Research
  • Arizona Research Center
  • ACRC/Arizona Clinical Research
  • Advance Pain Medicine
  • Eastgate Medical Center
  • University Osteoporosis Ctr
  • San Diego Arthritis & Osteoporosis Medical Clinic
  • Scripps Clinic Rancho Bernard
  • CNS Clinical Trials, Inc
  • Mountain View Clinical Research
  • Integrative Treatment Centers/Rocky Mtn Clin Res
  • Rocky Mountain Center for Clinical Research
  • Stamford Therapeutic Consortium
  • Medical Specialists of the Palm Beaches
  • University Clinical Research Deland
  • Drug Study Institute
  • Coastal Medical Research
  • Coastal Medical Research
  • Palm Beach Research Center
  • Gold Coast Research
  • Non-Surgical Orthopedic & Spine Center
  • Columbus Internal Medical Associates
  • MediSphere Medical Research Ctr.
  • Primary Care Research
  • Professional Clinical Research
  • Sound Medical At West Front Primary Care
  • Beth Israel Med Ctr Dept of Pain Medicine & Palliative Care
  • All-Trials Clinical Research, LLC
  • Keystone Clinical
  • Altoona Center for Clinical Research
  • University Orthopedics Center
  • Clinical Research Center of Reading, LLP
  • Low Country Rheumatology
  • Brown Clinic
  • Private Practice
  • Team Research of Central Texas
  • Radiant Research San Antonio Northeast
  • ACCU Clinical Research Trials, Inc
  • Wasatch Clinical Research
  • Advance Pain Management & Rehab
  • Evergreen Clinical Research Associates
  • Internal Medicine Northwest

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

BTDS

Placebo

Arm Description

Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)

Placebo to match BTDS 5, 10 or 20 mcg/h

Outcomes

Primary Outcome Measures

The Time (Days) From First Administration of Double-blind Treatment to the Development of Inadequate Analgesia at the Primary Osteoarthritis Pain Site.
Inadequate analgesia: "average pain over the last 24 hours" score for pain at primary osteoarthritis (OA) site ≥ 5 on any 2 days of any 7-day dosing period, on a scale from 0 - 10 (0 = no pain to 10 = pain as bad as you can imagine)or; >1000 mg/day acetaminophen for pain at primary OA site for ≥ 2 days in any 7-day dosing period, or; ingested nonstudy opioid analgesic medication for pain at primary OA site. Score: lowest score = shortest time to inadequate analgesia; highest score = longest time to inadequate analgesia.

Secondary Outcome Measures

Daily Maximum "Pain Right Now" Score for the Primary Osteoarthritis (OA) Pain Site
The daily maximum 'pain right now' score for the primary OA pain site was calculated over the last 7-day dosing period in the double-blind phase or the last 7-day dosing period prior to emergence of inadequate analgesia or discontinuation from the double-blind phase. Collected prior to ingestion of acetaminophen. "Pain right now" scale score for primary OA site on a scale from 0-10 (where 0= no pain and 10= worst pain you can imagine).

Full Information

First Posted
April 11, 2006
Last Updated
August 27, 2012
Sponsor
Purdue Pharma LP
search

1. Study Identification

Unique Protocol Identification Number
NCT00313846
Brief Title
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of the Buprenorphine Transdermal Delivery System in Subjects With Moderate to Severe Osteoarthritic Pain of Hip or Knee
Study Type
Interventional

2. Study Status

Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
April 2003 (undefined)
Primary Completion Date
June 2004 (Actual)
Study Completion Date
June 2004 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Purdue Pharma LP

4. Oversight

5. Study Description

Brief Summary
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe osteoarthritis pain of the hip and knee currently treated with oral opioids. The double-blind treatment intervention duration is 4 weeks during which time supplemental analgesic medication (acetaminophen) will be provided to all subjects in addition to study drug.
Detailed Description
Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Chronic pain, opioid, transdermal, osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
529 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BTDS
Arm Type
Experimental
Arm Description
Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo to match BTDS 5, 10 or 20 mcg/h
Intervention Type
Drug
Intervention Name(s)
Buprenorphine transdermal patch
Other Intervention Name(s)
Butrans™
Intervention Description
Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
Primary Outcome Measure Information:
Title
The Time (Days) From First Administration of Double-blind Treatment to the Development of Inadequate Analgesia at the Primary Osteoarthritis Pain Site.
Description
Inadequate analgesia: "average pain over the last 24 hours" score for pain at primary osteoarthritis (OA) site ≥ 5 on any 2 days of any 7-day dosing period, on a scale from 0 - 10 (0 = no pain to 10 = pain as bad as you can imagine)or; >1000 mg/day acetaminophen for pain at primary OA site for ≥ 2 days in any 7-day dosing period, or; ingested nonstudy opioid analgesic medication for pain at primary OA site. Score: lowest score = shortest time to inadequate analgesia; highest score = longest time to inadequate analgesia.
Time Frame
Double-blind phase ( 28 days): reaching "inadequate analgesia" on any 2 days of the 7-day dosing periods
Secondary Outcome Measure Information:
Title
Daily Maximum "Pain Right Now" Score for the Primary Osteoarthritis (OA) Pain Site
Description
The daily maximum 'pain right now' score for the primary OA pain site was calculated over the last 7-day dosing period in the double-blind phase or the last 7-day dosing period prior to emergence of inadequate analgesia or discontinuation from the double-blind phase. Collected prior to ingestion of acetaminophen. "Pain right now" scale score for primary OA site on a scale from 0-10 (where 0= no pain and 10= worst pain you can imagine).
Time Frame
7 days of the last dosing period of the double-blind phase, or the last 7-day dosing period prior to emergence of inadequate analgesia or discontinuation from the double-blind phase.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: clinical diagnosis of chronic osteoarthritis of the hip or knee for 1 year or longer. an average pain due to osteoarthritis of moderate, moderately-severe, or severe for the 14 days prior to enrollment. Exclusion Criteria: ingest opioid analgesics on a daily basis. ingest >2500 milligrams (mg) acetaminophen on a daily basis. require <20 mg or >80 mg of morphine (or opioid equivalents) per day for control of their osteoarthritis pain. Other protocol-specific exclusion/inclusion criteria may apply.
Facility Information:
Facility Name
Vista Medical Research
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85206
Country
United States
Facility Name
Arizona Research Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85012
Country
United States
Facility Name
Radiant Research
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
Facility Name
Arizona Research Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85023
Country
United States
Facility Name
ACRC/Arizona Clinical Research
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85715
Country
United States
Facility Name
Advance Pain Medicine
City
Bakersfield
State/Province
California
ZIP/Postal Code
93311
Country
United States
Facility Name
Eastgate Medical Center
City
Cypress
State/Province
California
ZIP/Postal Code
90623
Country
United States
Facility Name
University Osteoporosis Ctr
City
Loma Linda
State/Province
California
ZIP/Postal Code
92354
Country
United States
Facility Name
San Diego Arthritis & Osteoporosis Medical Clinic
City
San Diego
State/Province
California
ZIP/Postal Code
92108
Country
United States
Facility Name
Scripps Clinic Rancho Bernard
City
San Diego
State/Province
California
ZIP/Postal Code
92128
Country
United States
Facility Name
CNS Clinical Trials, Inc
City
San Francisco
State/Province
California
ZIP/Postal Code
94121
Country
United States
Facility Name
Mountain View Clinical Research
City
Denver
State/Province
Colorado
ZIP/Postal Code
80209
Country
United States
Facility Name
Integrative Treatment Centers/Rocky Mtn Clin Res
City
Westminster
State/Province
Colorado
ZIP/Postal Code
80021
Country
United States
Facility Name
Rocky Mountain Center for Clinical Research
City
Wheat Ridge
State/Province
Colorado
ZIP/Postal Code
80033
Country
United States
Facility Name
Stamford Therapeutic Consortium
City
Bridgeport
State/Province
Connecticut
ZIP/Postal Code
66060
Country
United States
Facility Name
Medical Specialists of the Palm Beaches
City
Atlantis
State/Province
Florida
ZIP/Postal Code
33462
Country
United States
Facility Name
University Clinical Research Deland
City
Deland
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
Drug Study Institute
City
Jupiter
State/Province
Florida
ZIP/Postal Code
33458
Country
United States
Facility Name
Coastal Medical Research
City
Orange City
State/Province
Florida
ZIP/Postal Code
32763
Country
United States
Facility Name
Coastal Medical Research
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
Palm Beach Research Center
City
W. Palm Beach
State/Province
Florida
ZIP/Postal Code
33409
Country
United States
Facility Name
Gold Coast Research
City
Weston
State/Province
Florida
ZIP/Postal Code
33331
Country
United States
Facility Name
Non-Surgical Orthopedic & Spine Center
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
Columbus Internal Medical Associates
City
Columbus
State/Province
Indiana
ZIP/Postal Code
47201
Country
United States
Facility Name
MediSphere Medical Research Ctr.
City
Evansville
State/Province
Indiana
ZIP/Postal Code
47714
Country
United States
Facility Name
Primary Care Research
City
Murray
State/Province
Kentucky
ZIP/Postal Code
42071
Country
United States
Facility Name
Professional Clinical Research
City
Cadillac
State/Province
Michigan
ZIP/Postal Code
49601
Country
United States
Facility Name
Sound Medical At West Front Primary Care
City
Traverse City
State/Province
Michigan
ZIP/Postal Code
49684
Country
United States
Facility Name
Beth Israel Med Ctr Dept of Pain Medicine & Palliative Care
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States
Facility Name
All-Trials Clinical Research, LLC
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Keystone Clinical
City
Altoona
State/Province
Pennsylvania
ZIP/Postal Code
16602
Country
United States
Facility Name
Altoona Center for Clinical Research
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
Facility Name
University Orthopedics Center
City
State College
State/Province
Pennsylvania
ZIP/Postal Code
16801
Country
United States
Facility Name
Clinical Research Center of Reading, LLP
City
West Reading
State/Province
Pennsylvania
ZIP/Postal Code
19611
Country
United States
Facility Name
Low Country Rheumatology
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29406
Country
United States
Facility Name
Brown Clinic
City
Watertown
State/Province
South Dakota
ZIP/Postal Code
57201
Country
United States
Facility Name
Private Practice
City
Dallas
State/Province
Texas
ZIP/Postal Code
75251
Country
United States
Facility Name
Team Research of Central Texas
City
Harker Heights
State/Province
Texas
ZIP/Postal Code
76548
Country
United States
Facility Name
Radiant Research San Antonio Northeast
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78217
Country
United States
Facility Name
ACCU Clinical Research Trials, Inc
City
Seguin
State/Province
Texas
ZIP/Postal Code
78155
Country
United States
Facility Name
Wasatch Clinical Research
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84107
Country
United States
Facility Name
Advance Pain Management & Rehab
City
Virgina Beach
State/Province
Virginia
ZIP/Postal Code
23454
Country
United States
Facility Name
Evergreen Clinical Research Associates
City
Edmonds
State/Province
Washington
ZIP/Postal Code
98026
Country
United States
Facility Name
Internal Medicine Northwest
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States

12. IPD Sharing Statement

Links:
URL
http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b
Description
Product Information

Learn more about this trial

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

We'll reach out to this number within 24 hrs